PMPR+iPRF+Vit.D
Phase 2Small molecule
PMPR+iPRF+Vit.D is one of 28 small molecule programs targeting Periodontitis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Periodontitis
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Flagyl
DDePuy Orthopaedics
Approved
Neoral
NovartisApproved
Voltaren
NovartisApproved
Crestor
AstraZenecaApproved
Biaxin
AbbVieApproved
Minocin
TTriax
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Floxin
WWim Janssens
Approved
Glucophage
EMD SeronoApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Periodontitis1 trial
Evaluation of iPRF With Vit.D As an Adjunct to Non-Surgical Therapy in the Treatment of Stage III Periodontitis
Not yet recruiting·—·Phase 2·NCT06570200·45 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PMPR+iPRF+Vit.D. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCairo University